BCM
LXRX icon

Blume Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Blume Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12 Buy
+5
New +$10 ﹤0.01% 358

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
SC
Sessa Capital New York $5.98B AUM 99.85% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Blume Capital Management's LXRX Position: Q2 2026 in Review

Blume Capital Management opened a new position in Lexicon Pharmaceuticals (LXRX) in Q2 2026: 5 shares worth $12. The stake represents ﹤0.01% of the portfolio and ranks #358 among its holdings.

149 funds tracked by Wall St. Rank hold LXRX as of Q2 2026.

  • Blume Capital Management held 5 shares of Lexicon Pharmaceuticals worth $12 as of Q2 2026.
  • Lexicon Pharmaceuticals was a new Blume Capital Management position in Q2 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Blume Capital Management's portfolio in Q2 2026, its #358 holding.
  • 149 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q2 2026.

Based on Blume Capital Management's 13F filing for Q2 2026, filed 27 Jul 2026.